Together in health we challenge the impossible
Our mindset and mission is to help create
a healthier world
Only One Way To Do It
Scientists and healthcare professional teams working tirelessly and driven to help patients and families as they experience the many dramatic challenges and triumphs in their wellness journeys.
In a complex system of care, we believe in
the simplicity of working together to help champion wellness
Count on our
global strength
750+
Million
patients worldwide
~25
Years
in global biosimilars
26K+
Employees In
83 countries and
23 manufacturing facilities
Get the
big news
December 9, 2025
Coya Therapeutics announces the first ALS patients have been enrolled in the ALSTARS Trial of COYA 302
August 25, 2025
FDA accepts Investigational New Drug (IND) application for COYA 302 and Phase 2 trial begins
June 17, 2025
Dr. Reddy's and Alvotech form a strategic partnership for a biosimilar candidate to Keytruda (pembrolizumab)
March 18, 2025
Dr. Reddy's and Alvotech team announce FDA acceptance of license for AVT03 (denosumab)
February 6, 2025
Dr. Reddy’s and Henlius sign licensing deal for investigational daratumumab biosimilar HLX15
December 14, 2023
Dr. Reddy’s and Coya to develop and commercialize COYA 302 for the treatment of ALS
Dedicated to treating diseases.
Passionate about improving lives.
Dr. Reddy’s Biologics is focused on solutions that weave together patients, partnerships, and purpose